
|Videos|March 14, 2017
Access to High Cost Drugs Remains a Challenge in Specialty
Author(s)Lauren Santye, Assistant Editor
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FAQ: Guidance for Pharmacists, SSRIs Under Scrutiny and Political Debate
2
Ensitrelvir Demonstrates Significant COVID-19 Post-Exposure Prophylaxis Efficacy in Phase 3 Trial
3
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
4
How Advanced Technology Is Reshaping Medication Safety and Pharmacy Practice
5



































































































































